Anand Nandkumar

Associate Professor, Strategy
Executive Director - SRITNE, Associate Dean - Centre for Learning and Teaching Excellence



Anand Nandkumar is an Associate Professor of Strategy, Executive Director for SRITNE at ISB, and Associate Dean - Centre for Learning and Teaching Excellence. He explores industry and firm level phenomena that influence innovation – the generation of new ideas and entrepreneurship – distribution and commercialization of new ideas. His research focuses on high technology industries such as pharmaceuticals, bio-technology and software, and it falls in between industrial organisation (IO), economics of technological change and strategy. Professor Nandkumar current work in the innovation stream examines the effect of stronger IPR on different aspects of innovation such as the influence of stronger patents on long run incentives for innovation or the influence of stronger patents on the functioning of Markets for Technology (MFT). In the entrepreneurship stream, his current work examines the influence of venture capitalists on entrepreneurial performance.

Professor Nandkumar graduated with a PhD in Public Policy and Management, with a focus in strategy and entrepreneurship from Carnegie Mellon University in 2008. Prior to his PhD, he worked for about 3 years with a startup in the Silicon Valley and prior to that in New York City with one of the world’s largest financial services firm. True to his expertise, at the ISB, Professor Nandkumar teaches Strategic Innovation Management and Strategic Challenges for Innovation based startups.



  • 2021 - Present: Executive Director - SRITNE, Indian School of Business
  • 2016 - Present: Associate Professor, Indian School of Business
  • 2019 - 2020: Associate Dean – RCI Management, Indian School of Business
  • 2018 - 2020: Research Director-CIE, Indian School of Business
  • 2016 - 2018: Associate Professor of Management, ESSEC Business School Asia Pacific Campus,Singapore
  • 2008 - 2016: Assistant Professor, Indian School of Business


In the Media

December 10, 2019: Why should there be Googles, when we celebrate Infosys?, .

April , 2018: Bringing together scientific research and commercial activity under one roof, The Economic Times.

March , 2014: Will the Ranbaxy imbroglio hurt brand India, Business Standard.

April , 2013: The new patent law, policy and strategy, Express Pharma.

April , 2013: A poorer big pharma, Business Today.

October , 2011: Was the TRIP worthwhile?, Forbes India.

Research & Publications